➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Medtronic
Dow
Merck
Mallinckrodt

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NICODERM CQ

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Nicoderm Cq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00086411 Comparing Smoking Treatment Programs for Lighter Smokers - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 2003-09-01 The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.
NCT00086411 Comparing Smoking Treatment Programs for Lighter Smokers - 1 Completed Peter Gariti Phase 2 2003-09-01 The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.
NCT00139516 Chinese Community Smoking Cessation Project Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2001-09-01 The study has two objectives/aims: Aim 1: To test the efficacy of the intervention among adult smokers with cardiovascular disease, pulmonary disease and diabetes mellitus related illnesses (later modified to Chinese adults with and without diseases); and Aim 2: To examine a set of measures (background, general health, psychosocial, and smoking process) that are associated with smoking cessation at 6 and 12 months
NCT00139516 Chinese Community Smoking Cessation Project Completed University of California, San Francisco N/A 2001-09-01 The study has two objectives/aims: Aim 1: To test the efficacy of the intervention among adult smokers with cardiovascular disease, pulmonary disease and diabetes mellitus related illnesses (later modified to Chinese adults with and without diseases); and Aim 2: To examine a set of measures (background, general health, psychosocial, and smoking process) that are associated with smoking cessation at 6 and 12 months
NCT00158171 Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 2002-04-01 Currently one in five high school students smokes. Smoking can harm adolescents well before they reach adulthood by causing a number of immediate, sometimes irreversible, health risks and problems. This study will compare the effectiveness of treatment with bupropion, a nicotine patch, or nicotine gum in supporting the reduction of smoking in adolescent smokers.
NCT00218296 Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 2006-11-01 Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has health risks associated with its use. While treatment programs that focus on stopping tobacco use may be effective, past research has shown that interventions that specifically focus on reducing tobacco use may be equally effective and may motivate individuals to eventually quit using tobacco. This study will compare the effectiveness of a ST reduction treatment program versus a usual tobacco cessation treatment program (immediate cessation) for reducing tobacco use in ST users.
NCT00289653 Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation Completed Centre for Addiction and Mental Health N/A 2005-09-01 Smoking while on nicotine patches will help subjects to reduce their expired carbon monoxide levels from the levels they were before they started using the patch. Subjects will also decrease their daily consumption of cigarettes, change how they smoke the cigarette, and will show reduced reactivity to smoking-related cues and reduced craving.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nicoderm Cq

Condition Name

Condition Name for Nicoderm Cq
Intervention Trials
Nicotine Dependence 11
Smoking Cessation 10
Tobacco Use Disorder 6
Smoking 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nicoderm Cq
Intervention Trials
Tobacco Use Disorder 17
Heart Diseases 2
Cardiovascular Diseases 2
Stress Disorders, Traumatic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nicoderm Cq

Trials by Country

Trials by Country for Nicoderm Cq
Location Trials
United States 21
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nicoderm Cq
Location Trials
North Carolina 12
Wisconsin 2
Minnesota 2
Missouri 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nicoderm Cq

Clinical Trial Phase

Clinical Trial Phase for Nicoderm Cq
Clinical Trial Phase Trials
Phase 4 5
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nicoderm Cq
Clinical Trial Phase Trials
Completed 16
Not yet recruiting 9
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nicoderm Cq

Sponsor Name

Sponsor Name for Nicoderm Cq
Sponsor Trials
National Institute on Drug Abuse (NIDA) 11
Duke University 9
Centre for Addiction and Mental Health 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nicoderm Cq
Sponsor Trials
Other 38
NIH 15
Industry 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Mallinckrodt
Harvard Business School
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.